首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Application of hydrazino and hydrazido linkers to connect benzenesulfonamides with hydrophilic/phobic tails for targeting the middle region of human carbonic anhydrases active site: Selective inhibitors of hCA IX
【24h】

Application of hydrazino and hydrazido linkers to connect benzenesulfonamides with hydrophilic/phobic tails for targeting the middle region of human carbonic anhydrases active site: Selective inhibitors of hCA IX

机译:Hydrazina和肼接头用亲水/抗卟吩吡啶胺与靶向人类碳酸酐中小区域的苯磺酰胺连接苯磺胺酰亚胺活性部位:HCA IX的选择性抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Herein we report the design and synthesis of three different sets of novel benzenesulfonamides (5a-e, 7a-e and 10a-d) incorporating hydrophilic/hydrophobic tails by hydrazido or hydrazino linkers. The newly synthesized benzenesulfonamides were examined in vitro for their inhibitory activity towards four human (h) carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, hCA I, II, IX and XII using a stopped-flow CO2 hydrase assay. All these isoforms were inhibited by the sulfonamides (5a-e, 7a-e and 10a-d) with variable degrees in the following K-1 ranges: 76.8-357.4 nM for hCA 1, 8.2-94.6 nM for hCA II, 2.0-46.3 nM for hCA XI, and 8.3-88.3 nM for hCA XII. The sulfonamide 7d exhibited potent anti-proliferative activity against breast MCF-7 cancer cell line under both normoxic and hypoxic conditions with IC50 values equal 332 +/- 0.06 and 8.53 +/- 0.32 mu M, respectively, which are comparable to the reference drug doxorubicin (IC50 = 236 +/- 0.04 and 8.39 +/- 0.25 mu M, respectively). Furthermore, 7d was screened for cell cycle disturbance and apoptosis induction in MCF-7 cells. It was found to persuade cell cycle arrest at G2-M stage as well as to alter the Sub-G1 phase, also, 7d resulted in a significant increase in the percent of annexinV-FITC positive apoptotic cells from 1.03 to 18.54%. Molecular docking study was carried out for 7d within the hCA IX and hCA XII active sites to rationalize the obtained inhibition results. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:在此,我们报告了三种不同的新苯磺酰胺(5a-e,7a-e和10a-d)的三种不同的新型苯磺酰胺(5a-e,7a-e和10a-d),其通过氢肼或肼滴剂掺入亲水/疏水尾。在体外检查新合成的苯磺胺酰胺,其朝向四种人(H)碳酸酐酶(HCA,EC 4.2.1.1)的抑制活性使用止动流CO2水碱分析,对四种人(H)碳酸酐酶(HCA,EC 4.2.1.1)同种型,HCA I,II,IX和XII。所有这些同种型被磺胺酰胺(5a-e,7a-e和10a-d)抑制在以下K-1的可变度范围内:76.8-357.4nm用于HCA 1,8.2-94.6nm,HCA II,2.0- 46.3nm用于HCA XI,8.3-88.3nm用于HCA XII。磺胺酰胺7d在常氧和缺氧条件下表现出对乳腺MCF-7癌细胞系的有效的抗增殖活性,分别具有IC 50值等于332 +/- 0.06和8.53 +/-0.32μm,其与参考药物相当多柔比星(IC50 = 236 +/- 0.04和8.39 +/- 0.25 mu m)。此外,在MCF-7细胞中筛选7D用于细胞周期扰动和凋亡诱导。发现在G2-M阶段进行细胞周期停滞,以及改变亚g1相,也是7d,导致Annexinv-Fitc阳性凋亡细胞百分比显着增加,从1.03〜18.54%。在HCA IX和HCA XII活性位点内进行分子对接研究7D,以合理化所获得的抑制结果。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号